Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.8%

29 terminated/withdrawn out of 196 trials

Success Rate

84.7%

-1.8% vs industry average

Late-Stage Pipeline

6 trials in Phase 3/4

Results Transparency

74%

119 of 161 completed trials have results

Key Signals

6 recruiting119 with results21 terminated8 withdrawn

Enrollment Performance

Analytics

Phase 2

135(72.6%)

Phase 1

42(22.6%)

Phase 3

5(2.7%)

N/A

3(1.6%)

Phase 4

1(0.5%)

186Total

Phase 2(135)

Phase 1(42)

Phase 3(5)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (196)

Showing 20 of 196 trials

NCT04699630Phase 2Completed

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Role: lead

NCT06974786Phase 2Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Role: lead

NCT05972135Phase 2Recruiting

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Role: lead

NCT06773910Phase 2Recruiting

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

Role: lead

NCT05748834Phase 2Recruiting

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Role: lead

NCT07011576Phase 2Recruiting

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Role: lead

NCT07372625Phase 1Recruiting

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Role: collaborator

NCT03977467Phase 2Completed

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Role: lead

NCT04402138Phase 2Completed

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Role: lead

NCT04200365Phase 2Terminated

A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)

Role: lead

NCT01761240Phase 1Completed

Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

Role: collaborator

NCT05948462Phase 2Withdrawn

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Role: lead

NCT02843074Phase 2Completed

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Role: lead

NCT02649673Phase 1Terminated

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Role: lead

NCT02422667Withdrawn

iCORE: Collaborative Orthopedics Outcomes Registry

Role: lead

NCT03436862Phase 2Completed

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Role: lead

NCT02859064Phase 2Terminated

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Role: lead

NCT02887248Phase 2Terminated

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Role: lead

NCT02356822Withdrawn

Sarah Cannon Outcomes Registry

Role: lead

NCT04209725Phase 2Terminated

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Role: lead